NeuPath Health Inc. (TSXV:NPTH)
0.6000
0.00 (0.00%)
At close: Jun 19, 2026
NeuPath Health Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, NeuPath Health stock has a consensus rating of "Buy" and an average price target of $0.77. The average 1-year stock price forecast is 28.33% higher than the current stock price, while the lowest is $0.58 (-3.33%) and the highest is $0.95 (+58.33%).
Price Target: $0.77 (+28.33%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 27, 2026.
Analyst Ratings
The average analyst rating for NeuPath Health stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Nov '25 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $0.58 | Buy | Maintains | $0.58 | -3.33% | Mar 27, 2026 |
Financial Forecast
Revenue This Year
93.00M
from 87.19M
Increased by 6.66%
Revenue Next Year
102.30M
from 93.00M
Increased by 10.00%
EPS This Year
n/a
EPS Next Year
n/a
Financial currency is CAD.
Revenue Forecast
| Revenue | 2026 | 2027 |
|---|---|---|
| High | 93.0M | |
| Avg | 93.0M | |
| Low | 93.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 |
|---|---|---|
| High | 6.7% | |
| Avg | 6.7% | |
| Low | 6.7% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | - | |
| Avg | - | |
| Low | - |
EPS Growth
| EPS Growth | 2027 |
|---|---|
| High | - |
| Avg | - |
| Low | - |